title: [Parathyroid hormone for disorders of calcium metabolism and metabolic bone diseases other than osteoporosis].
abstract: Recombinant human parathyroid hormone (PTH) analogues reduce fractures in patients with osteoporosis by enhancing bone formation and improving bone quality. Furthermore, many studies have demonstrated the efficacy of these analogues in diseases such as PTH-deficient hypoparathyroidism, bisphosphonate-related osteonecrosis of the jaw and hypophosphatasia. Further studies are needed to examine the long-term effects and the safety of these analogues in children and cancer patients.
authors.affiliation: Department of Medicine, University of Tokyo Hospital, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Seiji
authors.initials: S
authors.lastname: Fukumoto
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000188:drug therapy; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D002128:Calcium Metabolism Disorders / Q000188:drug therapy*; D006801:Humans; D007011:Hypoparathyroidism / Q000188:drug therapy; D007014:Hypophosphatasia / Q000150:complications / Q000188:drug therapy; D010024:Osteoporosis; D058866:Osteoporotic Fractures / Q000188:drug therapy / Q000209:etiology; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D010281:Parathyroid Hormone; D011994:Recombinant Proteins